BG Medicine this week reported first quarter revenues of $888,000, up 85 percent from $480,000 in the first quarter of 2012.

The company also announced that it had appointed Paul Sohmer as president and CEO, replacing Eric Bouvier, who it said will remain as a consultant.

The revenue increase was driven by $820,000 in sales of the company's BGM Galectin-3 test, nearly doubling the $416,000 it posted in Q1 2012. The remaining $68,000 in revenues came from BG Medicine's services business, up 6 percent from $64,000 a year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.